On January 7, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate at two virtual conferences in January (Press release, Cytori Therapeutics, JAN 7, 2022, View Source [SID1234598416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event H.C. Wainwright BioConnect Conference
Date January 10-13, 2022
Time Presentation available on demand starting January 10 at 7:00 a.m. ET

Event Biotech Showcase 2022
Date January 10-12 & 17-19, 2022
Time Presentation available on demand
A webcast of the H.C. Wainwright presentation will be available under the ‘Events’ tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com. A webcast replay will be accessible for 90 days following the event.

Investors interested in arranging a virtual meeting with the Company’s management during the Biotech Showcase 2022 conference should contact the conference coordinator. The Company’s Biotech Showcase presentation can be accessed on demand to qualified investors through a complimentary registration on the conference website here: Biotech Showcase Registration.